With an expected increase in cancer cases from 20 million in 2022 to nearly 30 million by 2040, the pressure to enhance the efficacy and efficiency of clinical trials is urgent. As one of the leading causes of death worldwide, cancer compels us to not only increase our research efforts but also to significantly improve them.

Advances in electronic clinical outcome assessments, or eCOAs, are crucial in this context, offering better patient engagement, more streamlined data collection, and improved operational efficiencies. By incorporating eCOA platforms into our clinical trials, we are responding proactively to a growing necessity while aiming to achieve more meaningful and effective patient outcomes.

The Challenges of Oncology Trials

Clinical trials are rarely straightforward, and in oncology, the challenges are especially complex. Trial sites and sponsors must navigate a range of obstacles that, if left unresolved, can jeopardize the entire study and delay critical research and life-saving treatments. Key hurdles in oncology trials include:

• Expansive Patient Populations: Oncology trials often span multiple countries and cultural contexts. Further complexities, such as language barriers and varied socioeconomic backgrounds and health literacy levels across different regions, require solutions that can adapt to a wide range of patient needs.
• Strict Data Collection: One of the most essential elements within a clinical trial is the collection of high-quality patient-reported outcomes to assess therapeutic impact. However, ensuring the consistency and reliability of data from disparate sources is no small feat.
• Unyielding Timelines: With ever-evolving regulatory demands and the need for rapid patient enrollment, sponsors are under constant pressure to accelerate trial startup and execution without compromising quality.
• Operational Complexity: Managing licensing with those who hold copyrights to assessments, coordinating numerous clinical sites, managing multi-language translations and ensuring uniformity across assessments add layers of logistical complexity to the trial process.

These hurdles drive trial sponsors to adopt innovative solutions that not only address these issues but can be integrated to enhance overall trial efficiency.

eCOA: Meeting Complex Trials with A Thoughtful Response

Traditional paper-based assessments are often time-consuming and unable to facilitate real-time data captured directly from patients. Modern-day eCOA technology allows data collection in real-time, reduces errors and minimizes administrative burdens associated with data management. The evolution of digital technology has led to eCOA platforms — tools specifically designed to simplify and streamline clinical trial processes — becoming central components of complex clinical trials.

Placing the Patient at the Core

At its heart, an eCOA platform enhances clinical trials by focusing on the patient experience. The devastating toll of cancer, including symptoms like fatigue, weight fluctuations and pain, demands solutions that acknowledge and adapt to these challenges. eCOA systems, with their intuitive interfaces and logically structured question pathways, are designed to make it easier for patients to provide input.

By simplifying questionnaires, these platforms ensure higher compliance rates and more reliable data collection. Patients equipped with user-friendly digital tools are more likely to consistently complete their assessments, which in turn improves the quality and integrity of the data collected. This patient-first approach not only helps to ensure accurate data is gathered, it also makes patients feel valued and understood throughout the trial process.

Pillars of an eCOA platform

Clinical trials, especially those addressing oncology, are often dynamic endeavors. To ensure that trials remain uninterrupted, it is essential for eCOA platforms to prioritize and integrate these three pillars:

• Efficient Global Integration: eCOA systems should focus on enhancing global trial efficiency by centralizing data collection and streamlining collaboration in languages used by services providers and sponsors. This will reduce overall time and effort required to manage large-scale multinational trials.
• Streamlining Operational Workflows: eCOA systems should streamline clinical trial workflows by automating administrative tasks. This integration with electronic data capture systems and utilization of application programming interfaces ensures seamless, harmonized data flow across sites, languages and regions.
• Agility in Adoption: Modern eCOA systems provide the agility to implement mid-study protocol updates in real time, allowing research teams to adapt quickly without disrupting trial progress or compromising data consistency.

A Global Case Study in Oncology

A recent global oncology trial provides a compelling example of these benefits in action. In this study, the sponsor deployed a custom library spanning 13 countries to support a large-scale oncology program. This platform facilitated assessments in more than two dozen languages and assisted in the procurement of validations and licenses required to conduct the trial. Managing such a complex trial presented significant operational challenges. In later phases of oncology trials, treatments often lead to quality-of-life issues, such as fatigue and other debilitating symptoms. As a result, trial staff must carefully balance the need for accurate data collection while minimizing the burden on patients.

These complexities highlight the need for streamlined solutions that prioritize both efficiency and patient well-being. In this trial, the custom-built library played a pivotal role in achieving this balance, cutting the sponsor’s timeline by 50% while improving both workflow and data reliability. Additionally, by ensuring data is captured more accurately and efficiently, the patients providing these key insights can be relieved of their tasks sooner, allowing them to focus on their health.

The Future of Oncology Research

As the pharmaceutical industry continues down the path of innovation, the role of digital solutions like eCOA platforms will increase. For oncology trials, where patient populations are small and logistical challenges are magnified, such tools offer a clear path toward more efficient patient-centric research.

Looking to the future, several trends are likely to influence the evolution of eCOA technology:

• Enhanced Integration: Continued improvements in API functionality will further streamline the integration of eCOA platforms with other clinical trial systems to reduce data silos and improve overall workflow efficiency.
• Artificial Intelligence and Analytics: The incorporation of AI-driven analytics could enable predictive modeling and more proactive trial management, helping sponsors anticipate and mitigate potential challenges before they become critical and reducing translation timelines for the migration process.
• Global Regulatory Harmonization: As digital data collection becomes the norm, we can expect further regulatory harmonization across regions, which will simplify the deployment of eCOA systems in multinational trials.
• Patient Empowerment: Future eCOA platforms may incorporate features that further engage patients, such as personalized interfaces and feedback loops that help them understand how their data is contributing to the development of new therapies.

The Solution: Advanced eCOA platforms

Today’s eCOA technology is already making a significant impact on oncology trials. With faster deployment, higher-quality data collection and enhanced workflows, eCOA platforms are accelerating how quickly clinical trials are completed eCOAs can address consistent hurdles, such as patient location, robust data collection and overall trial complexities, so sites and sponsors can reallocate resources to critical tasks. This shift will allow better management and efficient operations of oncology trials.

Looking ahead, eCOA platforms will continue to play a pivotal role in the advancement of oncology research. As cancer cases continue to rise, the demand for enhanced, patient-centered trials will become increasingly urgent. The ability for clinical trials to integrate digital solutions like eCOAs will be the pivotal step in enabling faster, more accurate and scalable research to end cancer.

About the Author: Piero Bindi

Disclaimer: The above article is written by an external contributor. While Drug and Device World checks for accuracy, we are not responsible for views expressed/content or accuracy of any information posted in the article, and shall not be responsible for any decisions made based on such information.